Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.53 |
| ▸ | RELA | Q04206 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6768585 | 0.99 | RAB9A (0.53) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8300040 | 0.86 | NOTUM (0.47) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6768621 | 0.83 | NPC1 (0.68) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL7100160 | 0.83 | SIGMAR1 (0.51) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL7099371 | 0.83 | NPC1 (0.73) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6765702 | 0.83 | SIGMAR1 (0.51) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7101741 | 0.82 | ALDH1A1 (0.50) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6775006 | 0.81 | NPC1 (0.66) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL7099545 | 0.81 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL7100142 | 0.81 | SIGMAR1 (0.55) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2003-08-14 | — | — | US | claimed |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2002-07-25 | — | — | US | claimed |
| US-6358993-B1 | TREATMENT OF NEUROLOGICAL INJURY AND NEURODEGENERATIVE DISORDERS; NEUROPROTECTIVE AGENTS; SUBSTITUTED INDOLINYL AND INDOLINYL GUANIDINE DERIVATIVES | CENES PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| US-6770668-B2 | INDOLINYL, 1,2,3,4-TETRAHYDROQUINOLINYL, 1,2,3,4-TETRAHYDRO ISOQUINOLINYL, BENZ(CD)INDOLINYL AND 5,6-DIHYDROPHEN ANTHRIDINYL COMPOUNDS; TREATING NEURODEGENERATIVE DISORDERS | WYETH | 2004-08-03 | — | — | US | disclosed |
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2003-08-14 | — | — | US | disclosed |
| US-6514990-B2 | Fused N-heterocylic rings substituted at the ring nitrogen with group of formula (R-N(-R1)-C(=NH)-); treating a neurodegenerative disease; N-(m-ethylphenyl)-1-indolinylcarboximidamide, for example | SCION PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | WYETH | 2002-07-25 | — | — | US | disclosed |
| US-6358993-B1 | TREATMENT OF NEUROLOGICAL INJURY AND NEURODEGENERATIVE DISORDERS; NEUROPROTECTIVE AGENTS; SUBSTITUTED INDOLINYL AND INDOLINYL GUANIDINE DERIVATIVES | CENES PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6025355-A | SUBSTITUTED INDOLINYL AND DERIVATIVES THEREOF, NEUROLOGICAL INJURY AND NEURODEGENERATIVE DISORDERS. | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0925300-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0925300-A4 | — | — | 1999-06-30 | — | — | EP | disclosed |
| WO-1999002145-A1 | COMBINATION DRUG THERAPIES COMPRISING AMINOGLYCOSIDE ANTIBIOTICS AND N,N'-DISUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-01-21 | — | — | WO | disclosed |
| WO-1997030054-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153763-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | RAB9A 1903/4885MEN1 2848/4885KMT2A 3542/4885 |
| US-20020099084-A1 | Pharmaceutically active compounds and methods of use | ACHE, PARK7, NLN | RAB9A 1903/4885MEN1 2848/4885KMT2A 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.